Breakthrough shot shields babies from deadly RSV

NCT ID NCT05110261

Completed Prevention Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a single dose of nirsevimab, a lab-made antibody, in 800 healthy preterm and term infants in China to see if it could prevent serious lung infections caused by RSV. The goal was to reduce doctor visits and hospital stays during the RSV season. Results showed the treatment was safe and effective at lowering the risk of RSV-related illness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lower respiratory tract disorder respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOWER RESPIRATORY TRACT INFECTION

Contacts and locations

Locations

Research Site

Beijing, 100191, China
Research Site

Changde, 415000, China
Research Site

Changsha, 410005, China
Research Site

Changsha, 410008, China
Research Site

Chengdu, 610000, China
Research Site

Chengdu, 610041, China
Research Site

Guangzhou, 510120, China
Research Site

Guangzhou, 510150, China
Research Site

Guangzhou, 510280, China
Research Site

Hangzhou, 310006, China
Research Site

Hangzhou, 310013, China
Research Site

Jiaxing, 314000, China
Research Site

Kunming, 650101, China
Research Site

Langfang, 065000, China
Research Site

Linfen, 041099, China
Research Site

Linfen, 41081, China
Research Site

Nanjing, 210009, China
Research Site

Ningbo, 315012, China
Research Site

Sanmenxia, 472000, China
Research Site

Sanya, 572000, China
Research Site

Shantou, 515041, China
Research Site

Shaoxing, 311800, China
Research Site

Shenzhen, 518106, China
Research Site

Suzhou, 215002, China
Research Site

Tangshan, 63003, China
Research Site

Tianjin, 300201, China
Research Site

Wenzhou, 325027, China
Research Site

Xinxiang, 453000, China
Research Site

Zhengzhou, 450018, China
Research Site

Zhongshan, 528400, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.